Allergy to Peanuts imPacting Emotions And Life (APPEAL): the impact of peanut allergy on children, adolescents, adults and caregivers in France.

Burden Clinical history Diagnosis France Peanut allergy Quality of life

Journal

Allergy, asthma, and clinical immunology : official journal of the Canadian Society of Allergy and Clinical Immunology
ISSN: 1710-1484
Titre abrégé: Allergy Asthma Clin Immunol
Pays: England
ID NLM: 101244313

Informations de publication

Date de publication:
2020
Historique:
received: 05 06 2020
accepted: 10 09 2020
entrez: 12 10 2020
pubmed: 13 10 2020
medline: 13 10 2020
Statut: epublish

Résumé

Peanut allergy (PA) has increased in developed countries and can have a dramatic effect on quality of life but data surrounding this is limited in France. Allergy to Peanuts imPacting Emotions And Life study (APPEAL) investigated the experience and impact of living with PA in France. Respondents affected by PA directly (children aged 8-12 years, teenagers aged 13-17 years, or adults aged ≥ 18 years) or indirectly (caregiver) completed either an online questionnaire (APPEAL-1, N = 198), or provided in-depth interviews (APPEAL-2, N = 32). Quantitative data was evaluated using descriptive statistics. Qualitative data was analysed thematically, using MAXQDA software. Of 198 responders in APPEAL-1, 88% stated that PA affects their daily activities, and 74% felt isolated as a result of living with PA. Feelings of worry about exposure to peanuts on social occasions where food is involved was reported by 91%. A total of 44% reported some restrictions in their job options, 85% in socializing. Psychological impact of PA included responders feeling emotions of frustration (89%), uncertainty (87%), and stress (93%) and 93% reporting encountering instances of feeling different due to their PA. Main factors that drove PA impact included social activities and relationships; whereas main coping strategies to avoid peanuts included monitoring, communication and planning. The analysis of French respondents from the APPEAL study demonstrates the impact and burden of PA on allergic children, teenagers, adults and their caregivers, and highlights the unmet need to be addressed.

Sections du résumé

BACKGROUND BACKGROUND
Peanut allergy (PA) has increased in developed countries and can have a dramatic effect on quality of life but data surrounding this is limited in France. Allergy to Peanuts imPacting Emotions And Life study (APPEAL) investigated the experience and impact of living with PA in France.
METHODS METHODS
Respondents affected by PA directly (children aged 8-12 years, teenagers aged 13-17 years, or adults aged ≥ 18 years) or indirectly (caregiver) completed either an online questionnaire (APPEAL-1, N = 198), or provided in-depth interviews (APPEAL-2, N = 32). Quantitative data was evaluated using descriptive statistics. Qualitative data was analysed thematically, using MAXQDA software.
RESULTS RESULTS
Of 198 responders in APPEAL-1, 88% stated that PA affects their daily activities, and 74% felt isolated as a result of living with PA. Feelings of worry about exposure to peanuts on social occasions where food is involved was reported by 91%. A total of 44% reported some restrictions in their job options, 85% in socializing. Psychological impact of PA included responders feeling emotions of frustration (89%), uncertainty (87%), and stress (93%) and 93% reporting encountering instances of feeling different due to their PA. Main factors that drove PA impact included social activities and relationships; whereas main coping strategies to avoid peanuts included monitoring, communication and planning.
CONCLUSION CONCLUSIONS
The analysis of French respondents from the APPEAL study demonstrates the impact and burden of PA on allergic children, teenagers, adults and their caregivers, and highlights the unmet need to be addressed.

Identifiants

pubmed: 33042203
doi: 10.1186/s13223-020-00481-7
pii: 481
pmc: PMC7541331
doi:

Types de publication

Journal Article

Langues

eng

Pagination

86

Informations de copyright

© The Author(s) 2020.

Déclaration de conflit d'intérêts

Competing interestsPC and BH are members of Team APPEAL and their patient advocacy organisations have received honoraria from Aimmune Therapeutics. GP is a member of Team APPEAL and has received honoraria from Aimmune Therapeutics for advice; honoraria from Bausch + Lomb for advice; honoraria from Mylan and Novartis; and research funding from Stallergènes and ALK-Abello. AV and RM are employees of Aimmune Therapeutics. SA and KG report consulting for Aimmune Therapeutics. RP reports consulting for Aimmune Therapeutics.

Références

Expert Rev Pharmacoecon Outcomes Res. 2010 Jun;10(3):269-81
pubmed: 20545592
Clin Exp Allergy. 2020 Aug 5;:
pubmed: 32757478
Pediatr Allergy Immunol. 2019 Nov;30(7):767-770
pubmed: 31172595
Pediatr Allergy Immunol. 2012 Aug;23(5):412-9
pubmed: 22554401
Clin Exp Allergy. 2016 Apr;46(4):610-20
pubmed: 26588036
Pediatrics. 2013 Jan;131(1):e10-7
pubmed: 23266926
Asian Pac J Allergy Immunol. 2018 Mar;36(1):22-26
pubmed: 28802031
Pediatr Allergy Immunol. 2003 Oct;14(5):378-82
pubmed: 14641608
Allergy. 2010 Jan;65(1):103-8
pubmed: 20078504
Chem Immunol Allergy. 2015;101:235-52
pubmed: 26022884
J Allergy Clin Immunol Pract. 2018 Mar - Apr;6(2):671-673.e7
pubmed: 29054706
Chronic Illn. 2011 Dec;7(4):255-66
pubmed: 21846662
Allergy. 2010 Feb;65(2):238-44
pubmed: 19796214
Eur Ann Allergy Clin Immunol. 2005 Feb;37(2):54-7
pubmed: 15859362
Clin Exp Allergy. 2017 Apr;47(4):530-539
pubmed: 27976436
Qual Life Res. 2015 Jun;24(6):1369-78
pubmed: 25394894
Clin Pediatr (Phila). 2011 Nov;50(11):1045-51
pubmed: 21685213
Allergy. 2011 Dec;66(12):1580-9
pubmed: 21958234
Allergy. 2020 Sep;75(9):2294-2308
pubmed: 32219884
Clin Exp Allergy. 2000 Aug;30(8):1135-43
pubmed: 10931121
J Allergy Clin Immunol Pract. 2014 Sep-Oct;2(5):639-41
pubmed: 25213068
J Paediatr Child Health. 2017 Jul;53(7):630-635
pubmed: 28608485
J Clin Nurs. 2017 Nov;26(21-22):3371-3381
pubmed: 28000310
Allergy. 2009 Mar;64(3):461-8
pubmed: 19076542
Allergy. 2015 Jun;70(6):616-24
pubmed: 25627424
Allergy. 2020 May 13;:
pubmed: 32400915
Allergy. 2020 May 21;:
pubmed: 32438514
Ann Allergy Asthma Immunol. 2020 Apr;124(4):379-384
pubmed: 31931105
J Allergy Clin Immunol Pract. 2020 Jan;8(1):352-354.e1
pubmed: 31326619
Allergy. 2016 Apr;71(4):505-13
pubmed: 26687298
Allergy Asthma Proc. 2017 Mar 1;38(2):88-91
pubmed: 28234046

Auteurs

Pascale Couratier (P)

Association Française pour la Prévention des Allergies (AFPRAL), 4, place Louis Armand - La Tour de l'Horloge, 75012 Paris, France.

Romain Montagne (R)

Aimmune Therapeutics, 10 Eastbourne Terrace, London, W2 6LG UK.

Sarah Acaster (S)

Acaster Lloyd Consulting, Ltd, 16 Woburn Pl, Bloomsbury, London, WC1H 0BS UK.

Katy Gallop (K)

Acaster Lloyd Consulting, Ltd, 16 Woburn Pl, Bloomsbury, London, WC1H 0BS UK.

Ram Patel (R)

Brainsell Ltd, 4 Duke Street, Richmond, TW9 1HP UK.

Andrea Vereda (A)

Aimmune Therapeutics, 10 Eastbourne Terrace, London, W2 6LG UK.

Guillaume Pouessel (G)

Department of Pediatrics, Children's Hospital, F-59056 Roubaix, France.
Pediatric Pulmonology and Allergy Department, CHU Lille, Lille University, F-59000 Lille, France.
Unité de pneumologie et allergologie pédiatriques, Hôpital Jeanne de Flandre, CHRU Lille et Université Lille2, 2 Avenue Oscar Lambret, 59037 Lille, France.

Classifications MeSH